Differences in drug-eluting stents used in coronary artery disease

American Journal of the Medical Sciences

Volumn 342, Issue 5, 2011, Pages 402-408

  Synetos, Andreas ^a,b   Toutouzas, Konstantinos ^a   Karanasos, Antonis ^a   Stathogiannis, Konstantinos ^a   Triantafyllou, Georgia ^a   Tsiamis, Eleutherios ^a   Lerakis, Stamatios ^b   Stefanadis, Christodoulos ^a,b  

^a UNIVERSITY OF ATHENS   (Greece)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drugeluting stents; Percutaneous coronary intervention; Restenosis; Stent thrombosis

Indexed keywords

EVEROLIMUS; PACLITAXEL; RAPAMYCIN; UMIROLIMUS; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; HEART INFARCTION; HUMAN; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; SAFETY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS;

EID: 80055041779     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3182123938     Document Type: Review

References (76)

1. Weintraub WS. The pathophysiology and burden of restenosis. Am J Cardiol 2007;100:3K-9K.
2. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-19. (Pubitemid 46376801)
3. Coolong A, Kuntz RE. Understanding the drug-eluting stent trials. Am J Cardiol 2007;100:17K-24K.
4. Farb A, Burke AP, Kolodgie FD, et al. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 2003;108: 1701-6. (Pubitemid 37243657)
5. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007;115:2435-41. (Pubitemid 46717966)
6. Guagliumi G, Sirbu V. Optical coherence tomography: high resolution intravascular imaging to evaluate vascular healing after coronary stenting. Catheter Cardiovasc Interv 2008;72:237-47.
7. Guagliumi G, Musumeci G, Sirbu V, et al. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents. JACC Cardiovasc Interv 2010;3:531-9.
8. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008;52:333-42. (Pubitemid 352001347)
9. Katoh H, Shite J, Shinke T, et al. Delayed neointimalization on sirolimus-eluting stents: 6-month and 12-month follow up by optical coherence tomography. Circ J 2009;73:1033-7.
10. Silva GV, Fernandes MR, Madonna R, et al. Comparative healing response after sirolimus-and paclitaxel-eluting stent implantation in a pig model of restenosis. Catheter Cardiovasc Interv 2009;73:801-8.
11. Wilson GJ, Nakazawa G, Schwartz RS, et al. Comparison of inflammatory response after implantation of sirolimus-and paclitaxel-eluting stents in porcine coronary arteries. Circulation 2009;120:141-9, 141-2.
12. Cook S, Ladich E, Nakazawa G, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009;120:391-9.
13. Drachman DE, Simon DI. Inflammation as a mechanism and therapeutic target for in-stent restenosis. Curr Atheroscler Rep 2005;7:44-9. (Pubitemid 40394229)
14. Hamilos M, Sarma J, Ostojic M, et al. Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses. Circ Cardiovasc Interv 2008;1:193-200.
15. Hamilos MI, Ostojic M, Beleslin B, et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol 2008;51:2123-9. (Pubitemid 351721001)
16. Kim JW, Seo HS, Park JH, et al. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus-versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction. J Am Coll Cardiol 2009;53:1653-9.
17. Moreno R, Fernandez C, Sanchez-Recalde A, et al. Clinical impact of in-stent late loss after drug-eluting coronary stent implantation. Eur Heart J 2007;28:1583-91. (Pubitemid 47227108)
18. Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 2005;111: 3435-42. (Pubitemid 40923397)
19. Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005;353:653-62. (Pubitemid 41175673)
20. Morice MC, Colombo A, Meier B, et al. Sirolimus-vs paclitaxeleluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006;295:895-904.
21. Galloe AM, Thuesen L, Kelbaek H, et al. Comparison of paclitaxeland sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA 2008;299:409-16. (Pubitemid 351185949)
22. de la Torre-Hernandez JM, Alfonso F, Hernandez F, et al. Drugeluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 2008;51:986-90. (Pubitemid 351318135)
23. Novack V, Cutlip D, Kleiman N, et al. In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus-or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv 2009;2:767-75.
24. Simonton CA, Brodie B, Cheek B, et al. Comparative clinical outcomes of paclitaxel-and sirolimus-eluting stents: results from a large prospective multicenter registry-STENT Group. J Am Coll Cardiol 2007;50:1214-22. (Pubitemid 47405129)
25. Nienaber CA, Akin I, Schneider S, et al. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry). Am J Cardiol 2009;104:1362-9.
26. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-8.
27. Kaltoft A, Jensen LO, Maeng M, et al. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry). J Am Coll Cardiol 2009;53:658-64.
28. Roy P, Bonello L, de Labriolle A, et al. Two-year outcome of patients treated with sirolimus-versus paclitaxel-eluting stents in an unselected population with coronary artery disease (from the REWARDS Registry). Am J Cardiol 2008;102:292-7.
29. Stefanadis C, Toutouzas K. Paclitaxel versus sirolimus: the battle is still ongoing. J Am Coll Cardiol 2009;53:665-6.
30. Austin D, Oldroyd KG, Pell JP. Observational studies of drug-eluting stents-some are more equal than others. EuroIntervention 2009;4:419, 421, 423.
31. Gurm HS, Boyden T, Welch KB. Comparative safety and efficacy of a sirolimus-eluting versus paclitaxel-eluting stent: a meta-analysis. Am Heart J 2008;155:630-9.
32. Schomig A, Dibra A, Windecker S, et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1373-80. (Pubitemid 47449734)
33. Sidhu S, Shafiq N, Malhotra S, et al. A meta-analysis of trials comparing Cypher and Taxus stents in patients with obstructive coronary artery disease. Br J Clin Pharmacol 2006;61:720-6. (Pubitemid 43794800)
34. Raber L, Juni P, Loffel L, et al. Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drugeluting stent implantation. J Am Coll Cardiol 2010;55:1178-88.
35. Raber L. Sirolimus-eluting stent compared with paclitaxel-eluting stent for coronary revascularization-late (SIRTAX-LATE) (abstract). Paper presented at Transcatheter Cardiovascular Therapeutics, San Francisco, 2009.
36. Onuma Y, Kukreja N, Piazza N, et al. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry. J Am Coll Cardiol 2009;54:269-76.
37. Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation 2009;119:680-6.
38. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008;299:1903-13. (Pubitemid 351574920)
39. Stone GW. SPIRIT III: 3-year results (abstract). Paper presented at Transcatheter Cardiovascular Therapeutics, San Francisco, 2009.
40. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010;375:201-9.
41. Byrne RA, Kastrati A, Kufner S, et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 2009;30: 2441-9.
42. Kastrati A. Clinical and angiographic results from a randomized trial of sirolimus-eluting and everolimus-eluting stents: ISAR-TEST 4 (abstract). Paper presented at Transcatheter Cardiovascular Therapeutics, San Francisco, 2009.
43. Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006;48:2440-7. (Pubitemid 44881222)
44. Leon MB, Mauri L, Popma JJ, et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxeleluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 55:543-54.
45. Leon MB. Late safety and efficacy of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: three-year follow-up from the ENDEAVOR IV trial (abstract). Paper presented at Transcatheter Cardiovascular Therapeutics, San Francisco, 2009.
46. Jensen LO, Tilsted HH, Thayssen P, et al. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. EuroIntervention 2010;5:898-905.
47. Meredith IT, Worthley S, Whitbourn R, et al. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv 2009;2:977-85.
48. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362:1663-74.
49. Rasmussen K, Maeng M, Kaltoft A, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet 2010;375:1090-9.
50. Meredith IT, Worthley SG, Whitbourn R, et al. Long-term clinical outcomes with the next-generation Resolute Stent System: a report of the two-year follow-up from the RESOLUTE clinical trial. EuroIntervention 2010;5:692-7.
51. Byrne RA, Kastrati A. Is there a preferable DES in diabetic patients? A critical appraisal of the evidence. Catheter Cardiovasc Interv 2008; 72:944-9.
52. Toutouzas K, Patsa C, Vaina S, et al. A preliminary experience report: drug-eluting stents versus coronary artery bypass surgery in patients with a single lesion in the proximal left anterior descending artery suffering from diabetes mellitus and chronic stable angina. Hellenic J Cardiol 2008;49:65-71. (Pubitemid 351631140)
53. Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or sirolimuseluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-70. (Pubitemid 41175674)
54. Kim JS, Lee BH, Ko YG, et al. Comparison of sirolimus-eluting stent and paclitaxel-eluting stent for long-term cardiac adverse events in diabetic patients: the Korean Multicenter Angioplasty Team (KOMATE) Registry. Catheter Cardiovasc Interv 2008;72:601-7.
55. Lee SW, Park SW, Kim YH, et al. A randomized comparison of sirolimus-versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus. J Am Coll Cardiol 2008;52:727-33.
56. Lee SW, Park SW, Kim YH, et al. A randomized comparison of sirolimus-versus paclitaxel-eluting stent implantation in patients with diabetes mellitus 2-year clinical outcomes of the DES-DIABETES trial. J Am Coll Cardiol 2009;53:812-3.
57. Tomai F, Reimers B, De Luca L, et al. Head-to-head comparison of sirolimus-and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study. Diabetes Care 2008;31:15-9.
58. Daemen J, Garcia-Garcia HM, Kukreja N, et al. The long-term value of sirolimus-and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J 2007;28:26-32. (Pubitemid 46134954)
59. Billinger M, Beutler J, Taghetchian KR, et al. Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients. Eur Heart J 2008;29:718-25. (Pubitemid 351431021)
60. Zhang F, Dong L, Ge J. Meta-analysis of five randomized clinical trials comparing sirolimus-versus paclitaxel-eluting stents in patients with diabetes mellitus. Am J Cardiol 2010;105:64-8.
61. Stettler C, Allemann S, Wandel S, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 2008;337:a1331.
62. Kumbhani DJ, Bavry AA, Kamdar AR, et al. The effect of drugeluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trials. Am Heart J 2008;155:640-7.
63. Frobert O, Lagerqvist B, Carlsson J, et al. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). J Am Coll Cardiol 2009;53:1660-7.
64. Kirtane AJ, Patel R, O'Shaughnessy C, et al. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus-and paclitaxel-eluting stents in patients with coronary artery disease. JACC Cardiovasc Interv 2009;2:967-76.
65. Stone GW. SPIRIT IV: a prospective, randomized trial comparing an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease. One year clinical results (abstract). Paper presented at Transcatheter Cardiovascular Therapeutics, San Francisco, 2009.
66. Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005;293:165-71. (Pubitemid 40095867)
67. Toutouzas K, Patsa C, Tsiamis E, et al. Everolimus-and zotarolimuseluting stents for bare metal stent in-stent restenosis treatment: a prospective study. J Interv Cardiol 2008;21:388-94.
68. Worthley MI, Anderson TJ, Traboulsi M, et al. Registry data evaluating the effectiveness of drug-eluting stents for the treatment of symptomatic in-stent restenosis. Heart Lung Circ 2006;15:300-5. (Pubitemid 44426255)
69. Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus-and paclitaxel-eluting stents. Circulation 2006;113:1108-13.
70. Nikolsky E, Mehran R, Turcot D, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 2004;94:300-5. (Pubitemid 38962693)
71. Toutouzas K. New generation drug-eluting stents implantation in patients with chronic kidney disease (abstract). Paper presented at American College of Cardiology Scientific Sessions, Atlanta, 2010.
72. Sukhija R, Aronow WS, Palaniswamy C, et al. Major adverse cardiac events in patients with moderate to severe renal insufficiency treated with first-generation drug-eluting stents. Am J Cardiol 105:293-6.
73. Jeong YH, Hong MK, Lee CW, et al. Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation. Int J Cardiol 2008;125:36-40. (Pubitemid 351305425)
74. Kim HS, Lee JH, Lee SW, et al. Long-term safety and efficacy of sirolimus-vs. paclitaxel-eluting stent implantation for acute ST-elevation myocardial infarction: 3-year follow-up of the PROSIT trial. Int J Cardiol 2011;147:253-7.
75. Lee CW, Park DW, Lee SH, et al. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. Am J Cardiol 2009;104: 1370-6.
76. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimuseluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363:136-46.